Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Liver Disorders

US Hepatology Partner

EU Hepatology Partner

Global Hepatology Partner

An Introduction to Liver Disorders

Hepatology covers hepatitis, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD), cirrhosis and rarer conditions such as autoimmune and cholestatic liver diseases. Despite numerous advances, liver-related mortality has remained stable for over 30 years. The World Health Organization has set targets for hepatitis C elimination by 2030. Immunotherapy and combination therapies have greatly increased the efficacy of the treatment of hepatocellular carcinoma (HCC). However, as a result of the increasing prevalence of obesity, NAFLD is reaching epidemic proportions and poses a major challenge to global public health. There is an urgent need for long-term management strategies and pharmacological interventions for NAFLD.

Our supporting partners do not constitute an endorsement of the content on this page.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Mark CompleteCompleted
BookmarkBookmarked

In the interview, Dr Paul Pockros discusses his presentation from DDW 2025 on the SPRING study (NCT04595825), which evaluated CM-101, a novel anti-CCL24 monoclonal antibody, in adults with primary sclerosing cholangitis (PSC). With no FDA-approved treatments for PSC, CM-101 showed promising safety, tolerability, and biomarker improvements over 48 weeks, supporting advancement to phase 3 trials.

34 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Dr Mitchell L Shiffman

Dr Mitchell L Shiffman explores the current and future management of primary biliary cholangitis

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT
Prof. Gideon Hirschfield, Prof. Sonja Ständer, Ms Michelle Clayton, Mrs Collette Thain MBE

A multidisciplinary team and a patient advocate discuss the management of cholestatic pruritus in primary biliary cholangitis (PBC).

Mark CompleteCompleted
BookmarkBookmarked

The EASL 2024 meeting offered a great opportunity for hepatologists from around the world to discuss the latest data and tackle challenges in liver disease. Metabolic dysfunction-associated steatohepatitis (MASH) was a hot topic, with several exciting studies making waves. This article ...

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Dr Palak Trivedi, Prof. Gideon Hirschfield

Watch two specialists in autoimmune liver disease discuss best practice in the management of primary biliary cholangitis, including assessing emerging therapies and personalization of care.

Developed by Touch
Coverage from: UEG Highlights

LIBERTY-EoE-TREET (NCT03633617) was a phase 3, randomized, 3-part study investigating the efficacy and safety of dupilumab in eosinophilic esophagitis (EoE). It was a pleasure to talk with Prof. Arjan Bredenoord (Amsterdam UMC, Amsterdam, the Netherlands) around his analysis of the LIBERTY-EoE-TREET ...

Developed by Touch
Coverage from: EASL Highlights

MYR301 (NCT03852719) is a phase 3 study evaluating the long-term efficacy and safety of bulevirtide in people living with chronic hepatitis delta infection (CHD). In this interview, Prof. Maria Buti (Vall d'Hebron University Hospital, Barcelona, Spain) discusses the results from the ...

Developed by Touch
Coverage from: EASL Highlights

touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D. Question: What are the ...

Coverage from: DDW Highlights

It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection. Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 ...

Coverage from: ACR Highlights

In Part 2 of our ACR Convergence Highlights coverage, Peter C Taylor (University of Oxford, Oxford, UK) discusses the results of an exploratory study into the association of Hydroxychloroquine (HCQ) use and the development of Non-Alcoholic Fatty Liver Disease (NAFLD) in ...

Load More...
Close Popup